Clinicopathological features and prognosis of patients with gastric stromal tumors
FANG Shixu1 LIN Bin1 WANG Feng1 LIU Tonglei2 ZHANG Tong2 LUO Huayou2
1.The First Clinical College of Kunming Medical University, Yunnan Province, Kunming 650032, China;
2.Department of Gastroenterology and Hernia Surgery, the First Affiliated Hospital of Kunming Medical University, Yunnan Province, Kunming 650032, China
Abstract：Objective To explore the clinicopathological features and prognostic factors of gastric stromal tumors further. Methods Clinical data, pathological characteristics and survival status of 108 patients with gastric stromal tumors admitted to the First Affiliated Hospital of Kunming Medical University from February 2009 to November 2012 were analyzed retrospectively. Survival analysis was used Kplan-Meier method to calculate 1, 3, 5-year survival rates. Log-rank test was used for univariate analysis and COX proportional hazards model was used for prognostic multivariate analysis. Results One hundred and eight patients were enrolled in the study. The male was 57 cases, the female was 51 cases, the age was (57.54±12.03) years, the operation time was (155.53±82.86) min, the intraoperative bleeding volume was (165.46±329.74) mL, the postoperative feeding time was (7.71±2.62) days, and the hospitalization days after operation were (11.80±7.54) days. The overall survival rates for 1, 3, 5 years were 100.0%, 91.6% and 76.3%. Univariate prognostic analysis showed that tumor size, mitotic numbe, modified NIH classification were closely related to prognosis of gastric stromal tumors (P < 0.05). Multivariate prognostic analysis showed that modified NIH risk classification (HR = 6.177, 95%CI: 1.348-28.299, P = 0.019) was an independent prognostic risk factor for patients with gastric stromal tumors. Conclusion Gastric stromal tumors are the most common digestive tract stromal tumors. The overall prognosis is good. Surgical resection is the main treatment. The modified NIH risk classification is the main risk factor affecting prognosis. The higher the risk, the worse the prognosis.
方仕旭1 林彬1 王峰1 刘童蕾2 张同2 罗华友2. 胃间质瘤临床病理特征及预后分析[J]. 中国医药导报, 2019, 16(20): 125-128.
FANG Shixu1 LIN Bin1 WANG Feng1 LIU Tonglei2 ZHANG Tong2 LUO Huayou2. Clinicopathological features and prognosis of patients with gastric stromal tumors. 中国医药导报, 2019, 16(20): 125-128.
[1] Connolly EM，Gaffney E，Reynolds JV. Gastrointestinal stromal tumours [J]. Br J Surg，2003，90（10）：1178-1186.
[2] Pisters PW，Blanke CD，von Mehren M，et al. A USA registry of gastrointestinal stromal tumor patients：changes in practice over time and differences between community and academic practices [J]. Ann Oncol，2011，22（11）：2523-2529.
[3] Soreide K，Sandvik OM，Soreide JA，et al. Global epidemiology of gastrointestinal stromal tumours （GIST）：a systematic review of population-based cohort studies [J]. Cancer Epidemiol，2016，40：39-46.
[4] Wang M，Xu J，Zhang Y，et al. Gastrointestinal stromal tumor：15-years′ experience in a single center [J]. BMC Surg，2014，14：93.
[5] Blay JY，Shen L，Kang YK，et al. Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours （ENESTg1）：a randomised phase 3 trial [J]. Lancet Oncol，2015，16（5）：550-560.
[6] Miettinen M，Lasota J. Gastrointestinal stromal tumors [J]. Gastroenterol Clin North Am，2013，42（2）：399-415.
[7] Yamamoto H，Oda Y. Gastrointestinal stromal tumor：recent advances in pathology and genetics [J]. Pathol Int，2015， 65（1）：9-18.
[8] Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor [J]. Hum Pathol，2008，39（10）：1411-1419.
[9] Mikami T，Nemoto Y，Numata Y，et al. Small gastrointestinal stromal tumor in the stomach：identification of precursor for clinical gastrointestinal stromal tumor using c-kit and alpha-smooth muscle actin expression [J]. Hum Pathol，2013，44（12）：2628-2635.
[10] Almagharbi SA，Fayoumi YA，Abdel-Meguid TA，et al. Extragastrointestinal stromal tumor of prostate [J]. Urol Ann，2018，10（4）：416-419.
[11] Huang H，Liu YX，Zhan ZL，et al. Different sites and prognoses of gastrointestinal stromal tumors of the stomach：report of 187 cases [J]. World J Surg，2010，34（7）：1523-1533.
[12] Rammohan A，Sathyanesan J，Rajendran K，et al. A gist of gastrointestinal stromal tumors：a review [J]. World J Gastrointest Oncol，2013，5（6）：102-112.
[13] Joensuu H，Hohenberger P，Corless CL. Gastrointestinal stromal tumour [J]. Lancet，2013，382（9896）：973-983.
[14] Akahoshi K，Oya M，Koga T，et al. Clinical usefulness of endoscopic ultrasound-guided fine needle aspiration for gastric subepithelial lesions smaller than 2 cm [J]. J Gastrointestin Liver Dis，2014，23（4）：405-412.
[15] Usta TA，Karacan T，Naki MM，et al. Comparison of 3-dimensional versus 2-dimensional laparoscopic vision system in total laparoscopic hysterectomy：a retrospective study [J]. Arch Gynecol Obstet，2014，290（4）：705-709.
[16] Agaimy A，Wunsch PH. Lymph node metastasis in gastrointestinal stromal tumours （GIST） occurs preferentially in young patients ≤ 40 years：an overview based on our case material and the literature [J]. Langenbecks Arch Surg，2009，394（2）：375-381.
[17] Koga T，Hirayama Y，Yoshiya S，et al. Necessity for resection of gastric gastrointestinal stromal tumors ≤ 20 mm [J]. Anticancer Res，2015，35（4）：2341-2344.
[18] Chen K，Zhou YC，Mou YP，et al. Systematic review and meta-analysis of safety and efficacy of laparoscopic resection for gastrointestinal stromal tumors of the stomach [J]. Surg Endosc，2015，29（2）：355-367.
[19] Ucar AD，Oymaci E，Carti EB，et al. Characteristics of emergency gastrointestinal stromal tumor （GIST） [J]. Hepatogastroenterology，2015，62（139）：635-640.
[20] Joensuu H，Eriksson M，Sundby Hall K，et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor：a randomized trial [J]. JAMA，2012，307（12）：1265-1272.
2019, Vol. 16 
京公网安备 11010502046598号